AFT Pharmaceuticals (ASX:AFP) Owner Earnings per Share (TTM): 0.08 (As of Mar. 2026) — 100% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
92 GF Score
Price A$3.19
GF Value A$3.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Owner Earnings per Share (TTM)?

AFT Pharmaceuticals ASX:AFP 92 Owner Earnings per Share (TTM) is 0.08 as of Mar. 2026, which is 100% below its 10-year median of 40.50. GuruFocus rates ASX:AFP with a GF Score™ of 92/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 474 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 65.4% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

AFT Pharmaceuticals's Owner Earnings per Share (TTM) ended in Mar. 2026 was A$0.08. It's Price-to-Owner-Earnings ratio for today is 39.88.


The historical rank and industry rank for AFT Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:

ASX:AFP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.71   Med: 40.5   Max: 96.27
Current: 38.33


During the past 11 years, the highest Price-to-Owner-Earnings ratio of AFT Pharmaceuticals was 96.27. The lowest was 20.71. And the median was 40.50.


ASX:AFP's Price-to-Owner-Earnings is ranked worse than
65.4% of 474 companies
in the Drug Manufacturers industry
Industry Median: 23.96 vs ASX:AFP: 38.33

AFT Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Mar. 2026 was A$0.09. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.12. It's PE Ratio (TTM) ratio for today is 26.81.

AFT Pharmaceuticals's EPS without NRI for the six months ended in Mar. 2026 was A$0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.12. It's PE Ratio without NRI ratio for today is 26.81.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


AFT Pharmaceuticals Owner Earnings per Share (TTM) Related Terms


AFT Pharmaceuticals Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Owner Earnings per Share (TTM) Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.06 0.09 0.06 0.08

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.00 0.06 0.00 0.08

ASX:AFP vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AFT Pharmaceuticals Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Price-to-Owner-Earnings falls into.


ASX:AFP
92GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

AFT Pharmaceuticals's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 12.3
Depreciation, Depletion and Amortization 3.1
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 6.9
Change In Working Capital 0.0
Shares Outstanding (Diluted Average) 104.9

1. Start with "Net Income" from income statement. AFT Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was A$12.3 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. AFT Pharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was A$3.1 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. AFT Pharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = A$6.9 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

AFT Pharmaceuticals's 5-Year Average Maintenance Capital Expenditure = A$6.9 Mil

5. "Change In Working Capital" is from cashflow statement. AFT Pharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.0 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. AFT Pharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 104.866 Mil.

AFT Pharmaceuticals's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 12.275 +3.083+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-6.944+0)/104.866
=0.08

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=3.19/0.08
=39.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.08 mean?
AFT Pharmaceuticals (ASX:AFP) has a Owner Earnings per Share (TTM) of 0.08 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on AFT Pharmaceuticals. This is 100% below median its historical median of 40.50. Over the past decade, AFT Pharmaceuticals' Owner Earnings per Share (TTM) has ranged from 20.71 to 96.27. According to the industry distribution chart, AFT Pharmaceuticals ranks #310 out of 474 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is AFT Pharmaceuticals' Owner Earnings per Share (TTM) too high?
AFT Pharmaceuticals' current Owner Earnings per Share (TTM) of 0.08 is 100% below median its 10-year median of 40.50. Over the past 10 years, this metric has ranged from a low of 20.71 to a high of 96.27. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.96. AFT Pharmaceuticals' value of 0.08 is 99.7% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #310 out of 474 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #310 out of 474 companies for Owner Earnings per Share (TTM). This places AFT Pharmaceuticals in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.96. AFT Pharmaceuticals' value of 0.08 is 99.7% below this benchmark. Historically, AFT Pharmaceuticals' own Owner Earnings per Share (TTM) has ranged from 20.71 to 96.27 over the past decade. While the company's 10-year median is 40.50 vs. the industry median of 23.96, AFT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.96, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Owner Earnings per Share (TTM) of 0.08 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on AFT Pharmaceuticals. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Owner Earnings per Share (TTM) is 0.08, which is 100% below median its own 10-year median of 40.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Owner Earnings per Share (TTM) is 0.08, which is 100% below median its 10-year median of 40.50 and 99.7% below the Drug Manufacturers industry median of 23.96. AFT Pharmaceuticals' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Owner Earnings per Share (TTM) is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for ASX:AFP:

  • Owner Earnings per Share (TTM): 0.08 (100% below median its 10-year median of 40.50)
  • GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
  • GF Score™: 92/100 with 4 warning signs
  • Industry Position: 99.7% below the Drug Manufacturers median (#310 of 474)

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
92GF Score

Get the complete analysis for ASX:AFP

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.19
Price
A$3.39
GF Value